To enable future exploitation of SOL-116 for the treatment of cancer, Lipum has applied for intellectual property protection and this international patent application will become public on 14 April 2024. lipum.se/eng/blog/mfn_n…

9 april startade teckningsperioden i Lipums företrädesemission. Kapitaltillskottet ska användas för att ta läkemedelskandidaten SOL-116 till kliniska fas II-studier, med målet att visa effekt på patienter med ledgångsreumatism. biostock.se/2024/04/lipums…

Lipum has been been granted 2,8 MSEK from Swelife. The project is a collaboration between Lipum, Karolinska Institutet, Stockholms stad and Linköpings universitet. lipum.se/eng/blog/mfn_n…

Lipum genomför en företrädesemission för att finansiera utvecklingen av SOL-116, med möjlighet att tillföra 187,2 Mkr vid full teckning, främst för att slutföra den pågående kliniska fas I-studien. Läs artikeln från BioStock här. biostock.se/2024/04/lipum-…

On April 29-30, Lipum's CEO, Ola Sandborgh, will participate in the LSX World Congress to attend investor meetings and present Lipum's ongoing development.

"We are delighted to be partnering with NorthX and it represents an important step as we move forward into our phase II trial", says CEO Ola Sandborgh. lipum.se/eng/blog/mfn_n…

At the moment, CEO Ola Sandborgh is at LSX - partnering for Life Science eXecutives congress. Take the opportunity to book a meeting and learn about Lipum's future development.

– I would like to extend a big thank you to everyone who participated in the rights issue. Our successful development can continue according to plan, says CEO Ola Sandborgh. Read the article from BioStock News here. biostock.se/en/2024/04/lip…

”Jag är mycket glad över att leda Lipums verksamhet och känner en stor tillfredsställelse över vad som uträttades under förra året”, säger Lipums VD Ola Sandborgh. #lipum #arsredovisning #fas_1 #fas_2 #lifescience lipum.se/blog/mfn_news/…

Ola Sandborgh summarizes his first six months as Lipum's new CEO: "Intense, enjoyable, and progress in the project that makes me very satisfied and proud!" #lipum #biostock #sol_116 #lifescience biostock.se/en/2024/08/lip…

"Peter has valuable and extensive experience in the role of CMO as well as pharmacology and clinical trials. His strong drive and commitment will contribute to the success of our continued clinical development", says CEO Ola Sandborgh. lipum.se/eng/blog/mfn_n…

– It is important for me to work in an organisation that not only has great ideas but also the capacity to turn those ideas into reality, and always with the patient in mind, says Peter Hovstadius, Lipum´s new CMO. biostock.se/en/2024/08/lip…

"It is very satisfying that all healthy subjects and patients are now included in the phase 1 study," says Lipum's CEO Ola Sandborgh. lipum.se/eng/blog/mfn_n…

CEO Ola Sandborgh comments on article: "It is very gratifying that we have reached this point in the development program and will be able to receive a final report within a few months." biostock.se/en/2024/09/lip…

Save the date: On November 4-6, Ola Sandborgh and Peter Hovstadius will participate at Bio-Europe 2024 in Stockholm. Welcome to meet them and learn more about Lipums first-in-class anti-BSSL antibody SOL-116 and the phase I study results. Register here: informaconnect.com/bioeurope/book…

Lipums vd Ola Sandborgh gästar Västra Hamnens studio och blir intervjuad av chefsanalytiker Martin Dominique om Lipums projekt, potential och planer. youtube.com/watch?v=bxPgwR…

- We are pleased with the successful collaboration with Karolinska Institutet. The research team’s work on BSSL is promising and could lead to more effective treatments for inflammatory diseases, says CEO Ola Sandborgh. biostock.se/en/2024/10/lip…

På fredag den 25 oktober bjuder G&W Fondkommission in Lipum till en presentation av kvartalsrapport och bolagets nuvarande status. Presentationen startar kl. 09:00. Registrera dig här: events.teams.microsoft.com/event/384c5b46…

Imorgon, 25 oktober kl 10:00, kommer VD Ola Sandborgh att kommentera kvartalsrapporten för juli-september 2024 i en webcast via Finwire. Se sändningen här: finwire.tv/webcast/lipum/… Välkommen!

lipum.se/eng/blog/mfn_n…